Inhibiting protein-protein interactions as an emerging paradigm for drug discovery.
Association of proteins into homo- and hetero-oligomers plays an important role in a plethora of biological phenomena. Inhibition of these interactions is increasingly recognized as a valuable new direction in drug design. In this mini-review we consider inhibition of protein misfolding and aggregation, molecules that disrupt enzyme quaternary structure, and signaling inhibitors, as emerging drugs.
Gerrard
J A
JA
School of Biological Sciences, University of Canterbury, Christchurch, New Zealand. juliet.gerrard@canterbury.ac.nz
Hutton
C A
CA
Perugini
M A
MA
D000818:Animals; D004194:Disease; D015195:Drug Design; D006262:Health; D006801:Humans; D011485:Protein Binding; D011506:Proteins / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects
D011506:Proteins